

Author Index, 1971-1975

(Volume numbers are
shown in **boldface**)

A

- Ackerman, L.V., **21**:
162-173, 220-226,
231-232, 270-281,
368-378; **22**: 40-54
Allen, D.W., **23**: 127-136,
193-200
Anderson, D.E., **24**:
130-136
Anglem, T.J., **23**: 330-333,
339-340
Appleton, J.R., **22**: 110
Arje, S.L., **21**: 365-367;
22: 292-295
Arlen, M., **24**: 78
Armstrong, D., **23**: 138-150
Armstrong, J.D., **25**:
242-257
Arnaud, C.D., **25**: 27-30
Auerbach, O., **21**: 78-94
Averette, H.E., **25**: 134-151

B

- Bacon, H.E., **21**: 235
Bagshaw, M.A., **22**: 242;
23: 81-90
Bailar, J.C., **23**: 106-110;
24: 253-254, 318-319,
372-374; **25**: 46-47,
107-110, 172-174, 238,
293-295, 344
Baillie, M., **24**: 49-56
Baker, C.G., **22**: 99-101
Baker, H.W., **22**: 30-39,
102-109, 159-162; **25**:
163
Ballantyne, A.J., **24**: 306
Barber, H.R.K., **22**: 357-359,
24: 339-347, 348-350; **25**:
160-161, 292, 334-337
Barkley, V., **24**: 191-192
Barclay, M., **21**: 202-212
Barrett, C.M., **21**: 102-108
Barrie, J.R., **21**: 112-119
Bartholomew, L.G., **21**: 234
Beardmore, G., **23**:
160-170
Beattie, E.J., **24**: 96-99
Bennett, A., **24**: 171-181

- Bergental, D.M., **23**:
244-255
Bergevin, P.R., **24**: 338
Billroth, T., **22**: 299-302
Block, J.B., **21**: 66-67,
130-131, 198-199,
265-266, 392-393; **22**: 63,
124-126, 192-193, 256,
318-319, 376-378; **23**:
64-65, 118-119, 182-183,
258-259, 323-325,
384-386; **24**: 57, 125-127,
182-184, 255, 315-317,
369-371
Blum, R.H., **24**: 322-331
Bodansky, O., **23**: 275-280
Bodey, G.P., **21**: 214-219
Bolt, R.J., **21**: 229
Bowden, L., **22**: 274-283;
23: 377
Bragg, D.G., **25**: 242-257
Brasfield, R.D., **21**:
174-183, 379-385; **22**:
176-183
Brayton, J.D., **24**: 233-234
Brendler, H., **25**: 101
Brobyn, T.J., **23**: 33-37
Brodsky, I., **24**: 149
Brunschwig, A., **24**:
363-367
Burchenal, J.H., **23**:
344-353
Burgess, G.H., **23**: 228-231
Burkitt, D.P., **22**: 349-355
Butcher, H.R., **21**: 235
Byrd, B.F., **24**: 290-293

C

- Cahan, W.G., **22**: 338-343
Caldwell, W.L., **22**:
185-186; **23**: 81-90
Canale, V.C., **24**: 66-77
Carbone, P.P., **23**: 285
Carter, S.K., **24**: 322-331
Case, R.W., **23**: 228-231
Chedd, G., **21**: 36-38
Chopra, H.C., **22**: 58-59
Christopherson, W.M., **21**:
282-287
Cohn, I., **24**: 148

- Cole, P., **23**: 127-136,
193-200
Cole, W.H., **21**: 231; **24**:
274-279
Coller, J.A., **25**: 286-290
Cooper, C., **21**: 214-219
Corman, M.L., **25**: 286-290
Crary, G.C., **24**: 36-39
Crary, W.G., **24**: 36-39
Crile, G., **23**: 334-338; **24**:
80
Crosby, C.H., **22**: 184-185
Curreri, A.R., **25**: 164
Cutler, S.J., **22**: 56-57

D

- Daly, T.E., **23**: 61
D'Angio, G.J., **24**: 332-335
Das Gupta, T.K., **21**:
174-183, 379-385; **22**:
176-183; **23**: 266-268
Davis, N.C., **23**: 43-45,
160-170
Derrick, W.S., **21**: 248-251;
23: 269-274
DeVita, V.T., **25**: 152-158
DeWys, W., **21**: 72-76
Diamond, L.K., **24**:
297-305
Docherty, J.J., **25**: 72
Dodd, G.D., **23**: 61
Dollinger, M.R., **22**:
138-147
Donaldson, M.H., **23**: 116
Donegan, W.L., **24**: 247
Dowdy, A.H., **21**: 156-161
Dunphy, J.E., **22**: 184

E

- Earle, J.D., **25**: 279
Eckles, N.E., **21**: 236-247,
306-316
Ewing, J., **22**: 95-98
Exelby, P.R., **21**: 95-101;
22: 202-208; **24**: 163-168

F

- Fairweather, W.E., **22**:

74-79

Farber, S., **24**: 297-305
 Farrow, J.H., **22**: 55
 Feller, W.F., **22**: 59,
 328-336
 Fennell, R.H., **21**: 184
 Feraru, F., **24**: 337
 Fisher, B., **22**: 186-187
 Foley, J.F., **23**: 354-361
 Folkman, J., **22**: 226-229
 Fortner, J.G., **22**: 148-150;
23: 180
 Frable, W.J., **21**: 252-253
 Fracchia, A.A., **22**: 243-244
 Freireich, E.J., **21**:
 214-219; **23**: 220-227
 Friedman, E.W., **24**:
 266-273
 Friedrich, E.G., **24**: 22-30
 Fuller, L.M., **21**: 236-247,
 306-316; **23**: 232-241

G

Gall, E.A., **21**: 102-108
 Gallagher, H.S., **22**: 60-61
 Garfinkel, L., **21**: 78-94;
25: 58-61
 Gellin, G.A., **24**: 234-235
 Gillman, A.M., **23**: 284
 Godlee, R.J., **24**: 171-181
 Godwin, J.T., **24**: 40-41
 Gold, P., **21**: 228-229
 Goldsmith, H.S., **22**:
 216-220; **23**: 42-43, 45
 Goldsmith, R.S., **25**: 27-30
 Good, R.A., **25**: 178-186
 Graber, E.A., **22**: 357-359;
24: 339-347, 348-350
 Grabstald, H., **23**: 81-90;
25: 82-90, 280
 Graham, E.A., **24**: 238-242
 Grant, R.N., **21**: 32-35,
 109-111, 158-161
 Gregor, D.H., **21**: 230;
22: 360-363
 Greene, E.M., **21**: 202-212
 Gumpert, S.L., **24**: 218-228
 Gusberg, S.B., **23**: 99-105;
25: 281-285

H

Halsted, W.S., **23**: 96-98
 Hammond, E.C., **21**: 78-94;
22: 327
 Harris, M.N., **24**: 218-228
 Hartman, P.V., **24**: 338
 Hawk, J.C., **24**: 280
 Hayes, D.M., **21**: 305
 Heidelberger, C., **25**: 101
 Helson, L., **25**: 264-277
 Helsper, J.T., **22**: 172-175
 Henderson, B.E., **25**:
 230-234
 Henderson, E.S., **24**:
 245-246
 Herbst, A.L., **22**: 292-295
 Hertz, R., **23**: 244-255
 Heston, V.J., **21**: 125-127,
 196-197, 258-261,
 328-331, 390-391; **22**:
 64-65, 127-128, 194-195,
 257-259, 324-326,
 384-385; **23**: 70-71,
 124-126, 187-188,
 260-262, 318-319,
 378-380; **24**: 60-61,
 119-122, 185-187,
 253-254, 318-319,
 372-374; **25**: 46-47,
 107-110, 172-174, 238,
 293-295, 344
 Hilbush, T.F., **23**: 244-255
 Hilleman, M.R., **24**:
 212-217
 Ho, D.H.W., **23**: 220-227
 Hodges, C.V., **22**: 232-240
 Hodgkin, T., **23**: 54-60
 Hodgkinson, C.P., **21**:
 365-367
 Holland, J.M., **25**: 121-133
 Holleb, A.I., **21**: 13-31, 71,
 201, 249-251, 288-291,
 332-333, 397; **22**: 2-20,
 26-29, 92, 99-101, 129,
 148-150, 200, 226-229,
 261, 338-343, 386-387;
23: 2-27, 38-41, 62-63,
 106-110, 117, 151-154,
 181, 275-280, 328, 341,
 362-366; **24**: 2-21, 42-46,

64, 83-86, 117-118,
 137-140, 212-217, 256,
 274-279, 320, 332-335;
25: 2-21, 22-26, 48,
 62-65, 112, 152-158,
 178-186, 239-240,
 258-263, 303-304
 Holyoke, E.D., **25**: 22-26
 Horn, R.C., **21**: 232; **24**:
 307
 Horsley, J.S., **22**: 74-79,
 311
 Horton, J., **24**: 233
 Huggins, C.B., **22**: 232-240
 Humphrey, L.J., **21**:
 134-140; **24**: 106
 Humphries, R.E., **23**:
 368-374
 Hutter, R.V.P., **21**: 3-10;
22: 90
 Huvois, A.G., **23**: 74-80

J

Jain, A.K., **24**: 79-80
 James, A.G., **24**: 32-35
 Jesse, R.H., **22**: 209-215,
 356
 Jewett, H.J., **24**: 244, 338
 Johnston, W.W., **21**:
 253-254

K

Kaplan, H.S., **25**: 306-319
 Kaufman, R.H., **24**:
 258-265, 307; **25**: 72-73
 Kaufman, R.J., **21**:
 202-212; **24**: 307
 Kelley, R.M., **22**: 241-242
 Ketcham, A.S., **23**: 38-41
 Kierland, R.R., **22**: 364-371
 Kim, D.H., **22**: 216-220;
23: 42-43, 45
 Kirman, D., **21**: 78-94
 Klein, E., **23**: 228-231
 Knapper, W.H., **21**:
 112-119
 Koehl, R.H., **21**: 2-10
 Kopf, A.W., **24**: 218-228
 Koss, L.G., **24**: 141-143

Krakoff, I.H., **23**: 208-219
Krant, M.J., **24**: 336; **25**:
98-100
Kwon, T.H., **24**: 339-347,
348-350

L

Lasker, M., **23**: 256-257
Laughlin, J.S., **21**: 334-340
Lawrence, W., **23**:
286-304; **25**: 175-176
Leber, R.E., **23**: 330-333
Lee, Y.-T.N., **24**: 104-105,
235
Leffall, L.D., **21**: 288-291;
22: 111-112; **24**: 42-46,
152-159
Levin, A.G., **23**: 74-80
Lewison, E.F., **22**: 58; **23**:
180
Li, M.C., **23**: 375-376
Lipkin, M., **21**: 227
Lipsett, M.B., **22**: 58; **23**:
244-255
Little, J., **23**: 160-170
Luckey, R.C., **24**: 281

M

MacComb, W.S., **24**:
229-232
Maier, W.P., **22**: 89-90; **23**:
33-37
Manos, N.E., **22**: 221-225
Marcove, R.C., **23**: 74-80
Markel, W.M., **22**: 187; **24**:
82
Markman, H.D., **23**:
354-361
Martel, W., **21**: 230-231
Martin, J.E., **22**: 62
Martland, H.S., **23**:
368-374
Mattingly, R.F., **24**: 22-30
McBride, C.M., **25**: 164
McCredie, K.B., **23**:
220-227
McHugh, P., **21**: 185
McKhann, C.F., **25**:
187-198

McLeod, R., **23**: 160-170
McPeak, C.J., **25**: 102
Mead, J.A.R., **25**: 103-104,
296-298, 346-347
Meigs, J.V., **25**: 33-39
Mercer, R.D., **24**: 297-305
Metcalf, D., **22**: 308-310
Michaelis, L.L., **22**: 74-79
Miké, V., **23**: 74-80
Miles, W.E., **21**: 361-364
Miller, T., **24**: 244
Moore, D.H., **22**: 59
Moore, G.E., **23**: 42
Mountain, C.F., **24**: 147
Muecke, E.C., **24**: 66-67
Müller, J., **23**: 307-312
Munnell, E.W., **24**: 106
Murphy, G.P., **24**: 282-288

N

Nelson, J.H., **21**: 184-185;
24: 243; **25**: 134-151
Newell, G.R., **25**: 338-343
Norman, F.W., **22**: 244

O

Olsson, C.A., **24**: 107
Osborne, R.L., **24**: 194-211
Osterkamp, R.W., **23**:
28-32
Overholt, B.F., **21**:
229-230; **25**: 74-81
Ozzello, L., **22**: 61

P

Paget, J., **21**: 303-304
Papanicolaou, G.N., **23**:
174-179
Patwardhan, V.C., **24**:
337-338
Peck, A., **22**: 284-291
Perez, F.M., **24**: 80-82
Pescovitz, H., **22**: 311
Pike, M.C., **25**: 230-234
Pittman, F.E., **24**: 281
Pivar, M.S., **25**: 291
Pott, P., **24**: 110-116
Prescott, D.M., **22**: 262-272

Price, E.B., **23**: 244-255
Purnell, D.C., **25**: 27-30
Pusztaszeri, G., **25**:
204-214

Q

Quan, S.H.Q., **24**: 148
Quinn, J.L., **21**: 292-301;
22: 243
Quinn, R., **23**: 160-170

R

Rapp, F., **25**: 215-229
Rauscher, F.J., **23**: 46-51
Ravdin, R.G., **22**: 185
Raventos, A., **21**: 63-65,
128-129, 190-192,
262-264, 322-324,
388-389; **22**: 66-67,
118-121, 186, 198-199,
252-253, 322-323,
381-383; **23**: 68-69,
122-123, 189-192,
326-327, 383; **24**: 62-63,
128, 190, 248-249,
308-311, 375-376; **25**:
40-41, 111, 166-169, 235,
301-302, 348
Rawls, W.E., **24**: 258-265;
25: 72-73
Richart, R.M., **25**: 134-151
Rickles, N.H., **22**: 163-171
Riggles, B.L., **25**: 27-30
Robins, M., **22**: 221-225
Röntgen, W.K., **22**:
153-157
Rosai, J., **21**: 163-173,
220-226, 270-281,
368-378; **22**: 40-54
Rosato, F.E., **22**: 89
Rosemond, G.P., **22**:
55-56; **23**: 33-37; **25**: 102
Rosenberg, I.N., **23**:
281-283
Rosenberg, S.A., **25**:
306-319
Rous, P., **22**: 23-25
Rundles, W., **24**: 137-140
Ryser, H.J.P., **24**: 351-360

S

- Scholz, D.A., **25**: 27-30
 Schroeder, J.M., **21**:
 156-157
 Schwartz, A.E., **24**: 266-273
 Seixas, F.A., **25**: 62-65
 Seman, G., **22**: 59-60
 Shah, J.P., **22**: 216-220;
23: 42-43, 45
 Sherman, L., **25**: 258-263
 Shils, M.E., **21**: 398-406
 Shimkin, M.B., **21**: 68-70,
 123-124, 193-195,
 255-257, 325-327,
 394-396; **22**: 68-69,
 122-123, 196-197,
 254-255, 320-321,
 379-380; **23**: 66-67,
 120-121, 184-186,
 263-264, 320-322,
 381-382; **24**: 58-59,
 123-124, 188-189,
 250-252, 312-314,
 377-378; **25**: 44-45,
 105-106, 170-171,
 236-237, 299-300, 345
 Silverberg, E., **21**: 13-31;
22: 2-20; **23**: 2-27; **24**:
 2-21; **25**: 2-21
 Silverberg, S.G., **25**:
 159-160
 Singer, J.J., **24**: 238-242
 Skipski, V.P., **21**: 202-212
 Smith, L.H., **25**: 27-30
 Smith, R.H., **23**: 313
 Snyder, R.E., **21**: 2-10; **22**:
 90-91
 Snyderman, R.K., **24**:
 246-247
 Solomon, K., **25**: 280
 Southam, C.M., **23**: 74-80
 Spratt, J.S., **21**: 32-35,
 233; **23**: 155-159; **24**:
 337
 Staff, A., **24**: 22-30
 Stanton, M.F., **21**: 58-62,
 125-127, 196-197,
 258-261, 328-331,
 390-391; **22**: 64-65,

- 127-128, 194-195,
 257-259, 324-326,
 384-385; **23**: 70-71,
 124-126, 187-188,
 260-262, 318-319,
 378-380; **24**: 60-61,
 119-122, 185-187,
 253-254, 318-319
 Stark, R.B., **22**: 303-307
 Stearns, M.W., **21**:
 233-234, 267-268; **23**:
 116; **24**: 100-103,
 160-162, 280
 Stein, J.J., **21**: 234-235;
24: 83-86
 Stein, R.S., **25**: 320-333
 Stewart, T.H.M., **22**: 60
 Stock, C.C., **21**: 202-212
 Strax, P., **22**: 88
 Strong, E.W., **21**: 112-119
 Sullivan, M.P., **23**: 232-241
 Sylvester, R.F., **24**:
 297-305

T

- Taylor, H.B., **22**: 57
 Taylor, R.M., **24**: 368
 Terebus-Kekish, O., **21**:
 202-212
 Terry, L., **23**: 362-366
 Terry, W.D., **25**: 198-203
 Thiessen, E.U., **22**: 87
 Thurman, W.G., **23**: 61
 Tompkins, R.R., **24**: 234
 Trelford, J.D., **24**: 151
 Turell, R., **23**: 91-93, 313

U

- Ulfelder, H., **24**: 31
 Ultmann, J.E., **21**: 342-359;
24: 150-151; **25**: 320-333
 Urban, J.A., **21**: 132-133;
22: 91-92

V

- Vaeth, J.M., **22**: 242-243
 Valk, W.L., **21**: 109-111
 Van Scott, E.J., **25**: 291

- Van Way, C.W., **25**:
 164-165
 Veidenheimer, M.C., **25**:
 286-290
 Venet, L., **22**: 87-88
 Viola, M.V., **21**: 46-57, 254
 Virchow, R., **25**: 93-100
 Volk, H., **23**: 354-361

W

- Walker, M.D., **25**: 114-120,
 280
 Wallace, T.I., **21**: 11-12
 Wang, C.-C., **22**: 356
 Watson, F.R., **23**: 155-159
 Watson, P., **21**: 214-219
 Weber, E., **25**: 73
 Weisburger, J.H., **21**:
 227-228
 Westmoreland, D., **25**:
 215-229
 Whitmore, W., **23**: 284
 Whitten, J.B., **23**: 28-32
 Will, J.J., **21**: 102-108
 Wilson, C.B., **22**: 241; **24**:
 31; **25**: 163
 Windhorst, D., **25**: 162
 Wizenberg, M., **23**: 81-90
 Wolfe, J.N., **22**: 88-89
 Wolff, J.A., **24**: 297-305
 Wood, G.C., **21**: 142-155,
 305; **22**: 80-86
 Wynder, E.L., **23**: 151-154

Y

- Yarlott, M.A., **25**: 187-197
 Young, C.W., **22**: 26-29

Z

- Zamcheck, N., **25**: 204-214
 Ziegler, J.L., **24**: 246
 Zippin, C., **22**: 57
 Zubrod, C.G., **23**: 202-207

Subject Index, 1971-1975

(Volume numbers are shown in **boldface**)

A

Abdominal-perineal resection for rectal cancer

First report of, **21**:361-364
Vs. fulguration, **21**:267-268

Actinomycin D

Combined with surgery and radiotherapy,
For Wilms' tumor, **23**:345
See also chemotherapy.

Adenocarcinoma

Of the lung, **25**:246-249
Of the oral cavity, **22**:38-39,212,213
Of the salivary glands, **24**:271,272-273
Of the thyroid, **25**:164-165

Adenoma of the lung, **25**:249-250

Adenoviruses and cancer, **25**:216

Adriamycin

See chemotherapy.

Aflatoxin B₁ and cancer, **24**:351,353

Alcoholism and cancer, **25**:62-65

Alimentary tract cancer

See surgery.

Alkylating agents

And cancer, **24**:351,353,354
See also chemotherapy.

Alpha-Fetoprotein (AFP)

Levels in liver carcinoma, **25**:210-211
Levels in testicular tumors, **25**:211

Alpha-H Fetoprotein (Alpha-HFP) for cancer detection, **25**:211-212

American Cancer Society

Role in cancer control, **23**:62-63

Aminopterin for treatment of childhood leukemia, **24**:297-305

Analgesics, **23**:270-271

Angiogenesis, **22**:226-229

Angiomatosis, **22**:176-179

Angiosarcoma, **22**:179-180

Anorexia and cancer, **21**:73-76

Appetite control and, **21**:73

Mechanisms of, **21**:75-76

Metabolic abnormalities in, **21**:73-75

Therapy for, **21**:76

Anticoagulants

For treatment of cancer, **24**:149

Metastases, **23**:38-41

Antigens

See immunology.

Aromatic amines and cancer, **24**:351, 353,354-355

Arteriography, **24**:86

B

Baillie, Matthew

Biography of, **24**:47-48

Basal cell carcinoma, **24**:220-223

Differential diagnosis of malignant melanoma and, **23**:167

BCG

See immunotherapy.

Benign lesions

Of the blood and lymph vessels, **22**:176-179

Resembling cancer, **21**:171-173

Bennett, Alexander Hughes

Biography of, **24**:169-170

Beta-S Fetoprotein (Beta-SFP) for detection of liver carcinoma, **25**:212

Billroth, Theodor

Biography of, **22**:296-298

Biochemistry

Advances in, **23**:275-280

Bulbrook study on breast cancer, **23**:280

CEA test, **23**:278-280

Enzyme tests, **23**:275-278

Oscar Bodansky's innovations in, **23**:328

Biography of

Baillie, Matthew, **24**:47-48

Bennett, Alexander Hughes, **24**:169-170

Billroth, Theodor, **22**:296-298

Brunschwig, Alexander, **24**:361-362

Burkitt, Denis, **22**:345-347

Ewing, James, **22**:93-94

Farber, Sidney, **24**:294-296

Gordlee, Rickman J., **24**:169-170

Graham, Everts A., **24**:236-237,337

Halsted, William, **23**:94-95

Hertz, Roy, **23**:242-243

Hodgkin, Thomas, **23**:52-53

Huggins, Charles, **22**:230-231

Martland, Harrison, **23**:367

Meigs, J.V., **25**:31-32

Miles, W. Ernest, **21**:360

Müller, Johannes, **23**:305-306

Paget, Sir James, **21**:302

Papanicolaou, George, **23**:171-173

Pott, Sir Percivall, **24**:108-109

Röntgen, Wilhelm, **22**:151-152

Rous, Peyton, **22**:21-22

Virchow, Rudolf, **25**:91-92

Biopsy, **21**:220-223

Excision, **21**:222-223

Frozen section, **21**:270-273

Incision, **21**:222

Liver,

For lymphomas, **21**:349-350

Microscopic examination of, **21**:273-279

Needle, **21**:220-222

Of the cervix, **25**:137-141

- Percutaneous transthoracic needle aspiration biopsy, **25:255**
- Bladder cancer**
 Chemotherapy for, **23:90**
 Diagnosis of, **23:82**
 Radiotherapy for, **23:85-90**
 Relationship of paraplegia with, **24:107**
 Staging of, **23:82-84**
 Surgery for, **23:84-90**
 Symptoms of, **23:81-82**
- Bleomycin**
See chemotherapy.
- Blood vessel tumors, 22:176-181**
 Benign, **22:176-179**
 Angiomatosis, **22:176-179**
 Glomus tumor, **22:179**
 Hemangioma, **22:176-179**
 Malignant, **22:179-181**
 Angiosarcoma, **22:179-180**
 Hemangiopericytoma, **22:180-181**
 Kaposi's sarcoma, **22:180**
- Blue nevus**
 Differential diagnosis of malignant melanoma and, **23:164**
- Bone Tumors**
 Benign, **24:198-203**
 Chondroblastoma **24:200**
 Enchondroma **24:199-200**
 Fibroxanthoma, **24:202-203**
 Giant cell tumor, **24:197,201-202**
 Hemangiomas, **24:203**
 Osteoblastoma, **24:201**
 Osteochondroma, **24:198-199**
 Osteoid osteoma, **24:200-201**
 Osteoma, **24:198**
 Diagnosis of, **24:196-197**
 Radiologic, **24:194-211**
 Malignant,
 Chondrosarcoma, **24:207-208**
 Diffuse endothelioma,
 First description of, **22:95-98**
 Fibrosarcoma, **24:209,210-211**
 Metastases in, **24:197-211**
 From breast primary, **21:306-311**
 Management of, **21:54-56**
 Myeloma, **24:204-205**
 Of the jaw, **22:107-109**
 Osteogenic sarcoma, **24:197,207,208-210**
 Reticulum cell sarcoma, **24:197,205-206**
 Squamous cell sarcoma, **24:244**
- Bonifacio Anticancer Goat Serum, 21:43-45**
- Brain cancer, 25:114-120,280**
 Chemotherapy for, **25:117-118**
 Combined modalities treatment for, **25:118-120**
 First excision for, **24:169-181**
 Malignant gliomas, **25:114-115,120**
 Meningiomas, **25:114-115**
- Neurodiagnostic tests for, **25:116**
 Radiotherapy for, **25:116-117**
 Scans in detection of, **24:31**
 Surgery for, **25:116**
 Symptoms of, **25:115-116,280**
- Breast**
 Cancer of,
 Adriamycin for, **24:325-326**
 Bilaterality of, **22:60-61,92,184**
 Carcinoembryonic antigen (CEA) measurement in, **25:204-210**
 Cross-reactivity of, **22:60**
 Detection of, **21:158-161; 22:62,88-89,90-91,92; 23:61; 24:82,290-293**
 Estrogen and, **24:307**
 Histology of, **22:58-59,61,89-91,184**
 Hormones and, **22:55,57-58,335**
 Incurable, **21:236-247**
 Therapy for **21:236-247,306-316**
 Metastatic liver lesions from,
 Management of **24:247**
 Paget's disease,
 First description of, **21:303-304**
 Pregnancy and, **22:184-185; 23:180**
 Prognosis of, **22:56-57,91-92**
 Relation with prolactin, **25:258-263**
 Risk factors for, **22:57,87,89,329-330**
 Treatment of, **22:55-56,58,62,89-91,184-187,241-244**
 American Cancer Society's policy statement on, **23:341-343**
 Controversy over surgerv, **23:330-333,334-338,339-340; 24:78-82**
 Delayed surgery, **21:132-133**
 Radical mastectomy, **24:78**
 First description of mastectomy, **23:96-98**
 Viruses and, **22:58,59,332,334-335**
 Attitudes about, **24:117-118**
 Cysts of,
 Needle aspiration for, **23:33-37**
 Symptoms associated with, **23:33-34**
 Treatment of chronic cystic mastitis, **24:246,247**
- Bronchography in lung cancer, 25:254**
- Brunschwig, Alexander**
 Biography of, **24:361-362**
- Burkitt, Denis**
 Biography of, **22:345-347**
- Burkitt's lymphoma**
 First description of, **22:348-355**
 Treatment of, **24:246**
 With chemotherapy, **23:345-346**
 And immunotherapy, **23:350-351**
 Cyclophosphamide, **25:152-153**

C

- Cachexia of neoplastic disease**
 Appetite control in, **21:73**
 Mechanisms of, **21:75-76**

- Metabolic abnormalities in, **21:73-75**
 Therapy for, **21:76**
- Carcinoembryonic antigen (CEA),**
25:22-26,204-210
 Evaluation of tests for, **23:278-280**
 Measurement of,
 For breast cancer, **25:209-210**
 For colon disorders,
 Benign, **25:206-207**
 Malignant, **25:22-26,204-209**
 For gastrointestinal cancer, **25:25-26**
 For lung cancer, **25:210**
 For ovarian cancer, **24:350**
 For pancreatic cancer, **25:25-26**
- Carcinogenesis, 24:351-360**
- Carcinoplacental Alkaline Phosphatase**
 for cancer detection, **25:212**
- Cecum, cancer of**
 Management of, **23:180**
- Cell reproduction, 22:262-272**
 Cell life cycle, **22:262-265**
 G₁ phase, **22:265-267**
 Regulation of cell production, **22:267-272**
- Cervical nodes, metastatic**
 Of unknown origin, **21:112-119; 24:229-232**
 Diagnosis, **24:229,230,231**
 Treatment, **24:229-232**
- Cervix,**
 Cancer of, **21:184-185; 25:134-150**
 Changing patterns of, **21:282-287**
 Cytologic screening for, **21:158-161, 282-287; 22:221-225**
 Detection of, **24:22-30; 25:134-141**
 By biopsy, **24:24; 25:137-141**
 By colposcopy, **24:26-29; 25:136-140**
 By conization, **24:25-26**
 By cytology, **24:22-23**
 With Schiller's solution, **24:23-24**
 5-Fluorouracil as a possible cause of, **24:151**
 Herpes genitalis and, **24:258-265**
 Staging of early, **24:243**
 Treatment of, **24:243**
 Dysplasia, **25:141-143,144-147**
 Carcinoma in situ, **25:141,143, 144,147-148**
 Stage I, **25:141,144,148-150**
 Stage II, **25:141,144**
 Wertheim operation for,
 First report of, **25:31-39**
 Precancerous lesions of,
 And pregnancy, **24:141-143**
- Chemotherapy, cancer**
 Adriamycin, **24:325-330**
 Clinical effectiveness of, **24:325-328**
 For breast cancer, **24:325-326**
 For bronchogenic carcinoma, **24:327**
 For leukemia, **24:327-328**
 For malignant lymphoma, **24:327**
 For other tumors, **24:328**
 For sarcoma, **24:326-327**
 Toxicity of, **24:328-330**
 Cardiac, **24:329-330**
 General, **24:328-329**
- Alkylating agents for ovarian cancer, **25:153**
 Aminopterin for leukemia remissions, **24:297-305**
 Bleomycin, **24:322-324**
 Dosage for, **24:324**
 Response rate from, **24:322-324**
 Toxicities of, **24:324**
- Combination, **25:155-158**
 For acute lymphatic leukemia of childhood, **25:156**
 For breast cancer, **25:157-158**
 For Hodgkin's disease, **25:156**
 Mechanisms of action of, **25:155-156**
- Complications of,
 Infections,
 Protections against, **21:214-219**
 Toxicity,
 Treatment for, **21:156-157**
- Cyclophosphamide,
 For Burkitt's lymphoma, **25:152-153**
- Editorial on, **22:200**
- Evaluation of new agents in the NCI
 Chemotherapy Program, **22:99-101**
- Factors in effectiveness of, **23:204-206**
- 5-Fluorouracil,
 And cancer of the cervix, **24:151**
 For colon cancer, **25:164**
 For skin cancer (topical), **23:228-231**
 Indications for, **23:229**
 Mode of action of, **23:228-229**
 Results of, **23:231**
 Side effects of, **23:230-231**
 Mechanisms of action of, **25:101**
- For bladder cancer, **23:90**
 For brain cancer, **25:117-120**
 For breast cancer, **24:347; 25:102**
 Incurable, **21:236-241**
- For Burkitt's tumor, **23:345-346**
 Combined with immunotherapy, **23:350-351**
- For choriocarcinoma, **23:344-345**
 Early report on, **23:244-255**
 Treatment of testicular, **25:88**
 Treatment with methotrexate, **25:152**
- For colon cancer, **23:285**
 For disseminated neuroblastoma, **25:268-269,272-277**
 For Hodgkin's disease, **23:346-347; 25:308,310-318**
 And other lymphomas, **21:356-358**
 Combined with radiotherapy, **23:232-241**
- For leukemia, **23:347-350**

- Combined with immunotherapy, **23**:349-350,351
 For malignant effusions, *See effusions*.
 For soft tissue sarcomas, **23**:268
 For stomach cancer, **23**:302
 For testicular tumors, **23**:345
 For Wilms' tumor, **23**:345; **24**:73-75,233
 Future of, **23**:204-206
 History of, **23**:203-204
 L-asparaginase, **23**:220-227
 Clinical results with, **23**:225-227
 History of, **23**:220
 Immunosuppressive activities, **23**:225
 Pharmacology of, **23**:221-223
 Resistance to, **23**:223
 Structure of, **23**:218-219
 Toxicity of, **23**:223-225
 Limitations of, **25**:153-155
 Mechanisms of action of, **23**:214-216
 Cell cycle specificity, **23**:217
 Drugs inhibiting protein synthesis, **23**:214-215
 Drugs modifying DNA functions, **23**:214-215
 Drugs modifying nucleic acid biosynthesis, **23**:214-215
 Mitotic inhibitors, **23**:216
 Specific metabolic inhibitors, **23**:216
 Steroid hormones balance, **23**:216
 Nomograms for determining body surface area, **23**:212-213
 Present status of, **23**:202-203,208-211
 Streptozotocin for malignant islet cell tumors of the pancreas, **25**:153
- Childhood cancer**, **24**:332-335
 Hodgkin's disease, **21**:95-101, **25**:306-319
 Malignant scrotal masses, **24**:163-168
 Management of, **24**:332-335
 Prognosis of, **24**:332
 Side effects from, **24**:332-334
See also sacrococcygeal teratomas and ovary.
- Chloromethyl methyl ether**, **24**:352-353
- Chondrosarcoma** of bone, **24**:207-208
- Choriocarcinoma**
 Chemotherapy for, **23**:344-345
 Early report on, **23**:244-255,375-376
- Classics in Oncology**
 Billroth's gastrectomy, **22**:299-302
 Burkitt's lymphoma, **22**:348-355
 Cerebral tumor,
 Surgical treatment of, **24**:169-181
 Editorial on, **21**:397
 Ewing's diffuse endothelioma of bone, **22**:95-98
 Halsted's radical mastectomy, **23**:96-98
 Hertz's chemotherapy for choriocarcinoma, **23**:244-255,375-376
 Hodgkin's disease, **23**:54-60
 Huggins's studies on prostatic cancer, **22**:232-240
 Leukemia,
 First description of, **25**:91-97
 First remission produced by drugs, **24**:294-305
 Lung,
 First removal of, **24**:236-242,337
 Martland's osteogenic sarcoma in watch dial painters, **23**:368-374
 Miles's operation, **21**:361-364
 Müller's structural characteristics of cancer, **23**:307-312
 Paget's disease, **21**:302-304
 Pancreas and duodenum,
 First resection for, **24**:361-367
 Papanicolaou's test, **23**:174-179
 Pathology,
 First systematic text of, **24**:47-48,49-56
 Röntgen's X-rays, **22**:153-157
 Rous's sarcoma virus, **22**:21-25
 Scrotal cancer,
 First description of, **24**:108-116
 Wertheim operation,
 Original report of, **25**:31-39
- Classification**, general
 Of carcinoma, **21**:370-371
 Of carcinoma in situ, **21**:371-372
 Of Hodgkin's disease and other lymphomas, **21**:343-345,374-377
 Of sarcoma, **21**:372-374
- Clustering**, cancer, **25**:230-234
 In Hodgkin's disease, **25**:231-233
 In leukemia, **21**:233-234
 Tests for validity of, **21**:231
- Coal tar** and cancer, **24**:351,353
- Codman's triangles** as a symptom of bone cancer, **24**:195
- Codman's tumor**, **24**:200
- Colon and rectum**
 Benign disease of the, **21**:233-234; **25**:78-80
 CEA detection of, **25**:206-207
 Cancer of the, **24**:152-159; **25**:80-81
 CEA measurement for, **25**:22-26,204-209
 Detection of,
 By proctosigmoidoscopy, **23**:354-361; **25**:286-290
 Using guaiac slide technique, **22**:360-363
 Diagnostic techniques for, **21**:230; **24**:154-157
 Differential diagnosis of, **24**:157-159, 281
 Digital rectal exam for, **24**:100-103
 Endoscopic examination for, **24**:160-162
 Etiologic factors in, **21**:227-229; **23**:151-154
 5-Fluorouracil as a surgical adjuvant

for, **25:164**
Histology of, **21:227,232**
Incidence of, **21:233; 23:151-152**
Preoperative administration of antibiotics for, **23:116**
Recurrent,

Chemotherapy and radiation therapy for, **23:285**

Survival rates for, **21:229**

Symptoms of, **21:234; 24:100, 152-154, 160**

Therapy for, **21:231-232,234-235**

Variables of metastatic, **21:32-35**

Leiomyosarcoma of, **25:102**

Polyps of the,

Management of, **23:91-93,313**

Sessile, **24:148**

Colonoscopy, 25:74-81

For disease detection,

Cancer, **25:80-81**

Colitis, **25:78-80**

Diverticulosis, **25:78**

Indications and contraindications, **25:74**

Colposcopy in examination for cervical neoplasia, **24:26-29; 25:136-140**

Communications techniques

In cancer management, **21:143-155**

Editorial on, **21:200-201**

Complications

Of cancer chemotherapy, **21:156-157**

Protection from, **21:214-219**

Of Hodgkin's disease and other lymphomas, **21:351-355**

Compound nevus and differential diagnosis of malignant melanoma, **23:162**

Conization of the cervix, **24:25-26**

Contraceptive pills and stilbestrol, 24:31

Contreras Methods for cancer, **21:317-321**

Cryosurgery for cancer, **22:338-343**

Cutaneous lesions suggesting internal cancer, **22:364-371**

Cyclophosphamide for Burkitt's lymphoma, **25:152-153**

Cyclotron in the production of radionuclides, **21:334-340**

Cysts

See breast.

Cytology

Cell reproduction, **22:262-272**

Detection of cervical cancer by, **21:223-226, 282-287; 22:221-225; 24:23-24,143**

And mammography, **21:158-161**

Diagnostic, **21:223-226**

Of malignant effusions, **21:47-48**

Examination of surgical specimens by, **24:40-41**

Exfoliative,

And oral cancer, **22:163-171**

Rapid smear technique, **24:41**

D

Death and the cancer patient, **24:256,336**

Decisions in cancer management, **23:155-159**

Patient's role in, **23:181**

Diagnosis, cancer

Of colorectal cancer, **22:360-363**

Of malignant effusions, **22:138-139**

Of oral tumors, **22:31-39,102-108**

Of ovarian cancer in postmenopausal women, **22:357-359**

Of sacrococcygeal teratomas in children, **22:204-206**

Of vaginal cancer, **22:293**

Techniques for,

Ancillary studies, **21:277-281**

Biochemical tests, **23:275-280**

Biopsy, **21:220-223**

Cytology, **21:223-226**

Frozen section, **21:270-273**

Gross and microscopic examination, **21:273-277**

Radionuclidic scanning, **21:292-301, 334-340**

Specimen roentgenography of the breast, **21:2-10,11-12**

Dial Access Programs for cancer information, **21:144-152; 22:80-86**

Development of, **22:83-86**

In treatment decisions, **22:82-83**

In emergencies, **22:82**

In referral, **22:82**

Diet

See nutrition.

Digital rectal examination

See colon and rectum

Dye-light therapy for herpes simplex virus infections, **25:72-73**

Dysplasia, cervical, 25:141-143

Treatment of, **25:144-147**

E

Editorials

Act to conquer cancer, **21:332-333**

Breast carcinoma,

Management of, **24:78-82**

Women's attitudes regarding, **24:117-118**

Bronchus removal for carcinoma, **24:337**

Cancer chemotherapy—progress and promise, **22:200**

Cancer control, costs, benefits and, **24:64**

Cancer information center, a shared re-

- sponsibility, **21:200-201**
 Cancer nursing—something old, something new, **24:191-192**
 Cancer patient—too often alone, **22:129**
 Cancer therapy—the patient's decision?, **23:181**
 Case against delayed operation for breast cancer, **21:132-133**
 Cookbook cancer therapy, **23:117**
 Do you mind if I smoke?, **25:303-304**
 Environment and cancer, **22:327**
 Every day is precious, **22:70-72**
 Forget the laboratory report?, **23:328**
 Fruits, vegetables and cancer dimensions, **25:112**
 Comments on, **25:278-279**
 Humanism and cancer, **22:386-387**
 International campaign against cancer, **24:368**
 Introducing cancer into the curriculum, **25:175-176**
 Oncologist and cancer management, **24:320**
 Patient's right to die, **24:256**
 Personal tribute to Sidney Farber, **23:256-257**
 Peyrihle's quest and modern oncology, **21:397**
 Rectal cancer, to burn or not to burn, **21:267-268**
 Role of the private sector in cancer control, **23:62-63**
 Some facts about the cancer effort, **25:239-240**
 Spirit of adventure: a personal tribute to Wendell G. Scott, **22:261**
 Surgical treatment of breast cancer, **23:341**
 Worthless cancer remedies, **21:71**
 25 Years of Ca-A Cancer Journal for Clinicians, **25:48**
- Effusions, malignant**
 Diagnosis of, **22:138-139**
 Management of recurrent, **22:138-147**
 Chemotherapy, **22:140-143,144-145**
 5-Fluorouracil, **22:143**
 Nitrogen mustard, **22:140-141,144**
 Quinacrine, **22:142,144**
 Thio-TEPA, **22:142,143**
 Radioactive isotopes, **22:143-146**
 Surgery, **22:146**
 Pathogenesis of, **22:139-141**
- Embryonal carcinoma,**
 Treatment of testicular, **25:88**
- EMI scanner, 24:85-86**
Emotional crises and cancer, 24 :36-39
Enchondroma, 24:199-200
Endocrine ablation for incurable breast cancer, 21:236-241
Endometrial cancer, 23:99-105
 Adenomatous hyperplasia, **23:99-101,**
- 103**
 Carcinoma in situ, **23:99-100**
 Diagnosis of, **23:101-102**
 Hormonal relations in, **23:104**
 Menopause and patients at high risk of, **23:100-103**
 Treatment of, **23:102-105**
- Endoscopic examination of the colon and rectum, 24:160-162**
Environmental factors in cancer, 22:327
Epidemiology of cancer, 21:13-31, 402-404; 22:2-20; 23:2-27; 24:2-21; 25:2-21, 338-343
Epidermoid carcinoma of the lung, 25:244-245
Epithelial tumors of the ovary in children, 25:335
Epstein-Barr virus
 See virus.
- Erythroleukemia**
 Prognosis of, **24:245**
 Treatment of, **24:245-246**
- Erythema as a sign of internal cancer**
 Diffuse and variable, **22:365-369**
 Localized, **22:365,366**
- Esophageal cancer, staging of, 25:50-57**
 General rules, **25:50-51**
 Survival rates by stage, **25:56-57**
 TNM system, **25:50-55**
- Estrogen**
 And breast cancer, **24:307**
 And gynecologic cancer, **25:291**
- Ewing, James**
 Biography of, **22:93-94**
- Ewing's tumor, 24:197,206-207**
 First description of, **22:95-98**
- Examination**
 Of the breast, **24:290-293**
 Of the colon and rectum, **24:160-162**
 Of the head and neck, **24:32-35**
- Eye**
 Treatment of melanoma of, **23:284**

F

- Farber, Sidney**
 Biography of, **24:294-296**
 Obituary of, **23:256-257**
- Feline leukemia-sarcoma complex, 24: 216-217**
Ferguson plant products for cancer, 22:113-117
Fetal sulfoglycoprotein antigen (FSA) in gastric disorders, 25:212
Fibrosarcoma, 24:209,210-211
Fibroxsanthoma, 24:202-203
Fluoroscopically assisted studies of lung cancer, 25:253-255
5-Fluorouracil
 See chemotherapy.
- Frozen section in the diagnosis of**

cancer, **21:270-273**

Fulguration vs. abdominal-perineal resection for rectal cancer, **21:267-268**

Functioning of tumors, **22:41-45,53**

G

Gamma-Fetoprotein (Gamma-FP) in cancer detection, **25:212**

Ganglion, **21:383**

Gastrectomy

First report of, **22:296-302**

Gastrointestinal disorders

CEA measurement in, **25:25-26**

Fetal sulfoglycoprotein antigen (FSA) detection of, **25:212**

Germ cell tumors of the ovary, **24:344-345**; **25:335-336**

Gerson Method of cancer treatment, **23:314-317**

Genetics

See *heredity*.

Giant cell tumors of the bone, **24:197**, **201-202**

Of the tendon sheath, **21:383-384**

Gliomas, malignant, **25:114-115,120**

Glomus tumor, **22:179**

Godlee, Rickman John

Biography of, **24:169-170**

Gonadal stromal tumors of the ovary, **25:336-337**

Gonadoblastoma of the ovary, **24:345-346**; **25:336**

Grading of tumors, **21:368,377**

Graham, Everts A.

Biography of, **24:236-237,337**

Grape diet, **24:144-146**

Gross surgical specimens

Examination of, **21:273-277**

Gynecologic

Cancer and estrogens, **25:291**

Examination, **25:281-285**

H

Haemotoxylon dissolved in Dimethylsulphoxide (D.M.S.O.), **21:386-387**

Halsted, William S.

Biography of, **23:94-95**

Handwriting test for cancer, **21:120-122**

Head and neck cancer

Bleomycin in treatment of, **24:322-323**

Examination of, **24:32-35**

Incidence of, **21:288-289**

Metastases of, **21:112-119**

Radiation for, **23:61**

Surgery for, **21:290-291**; **22:110-112**

Hemangioma

Of the blood and lymph vessels, **22:176-179**

Of the bone, **24:203**

Hemangiopericytoma, **22:180-181**

Heredity and cancer, **24:130-131**

Applications of, **24:135**

Nature of genetic deficiency, **24:134-135**

Two mutational model for, **24:131-134**

Herpes simplex infections

Controversy over dye-light therapy for, **25:72-73**

Herpesviruses

See *virus*.

Hertz, Roy

Biography of, **23:242-243**

Highlighting Cancer Chemotherapy

Reports, **21:66-67,130-131,198-199,265-266,392-393**; **22:63,124-126,192-193,256,318-319,376-378**; **23:64-65,118-119,182-183,258-259,323-325,384-386,394**; **24:57,125-127,182-184,255,315-317,369-371**; **25:42-43,103-104,296-298,346-347**

Hodgkin's disease, **23:346-347**; **25:306-319**

Classification of, **21:374-377**

In children, **21:95-101**

Clustering in, **25:231-233**

Diagnosis of, **25:306-307**

First description of, **23:54-60**

Prognosis of, **25:318-319**

Staging of, **25:307-309**

Treatment of, **25:308-318**

Chemotherapy, **25:308-318**

Bleomycin, **24:322-323**

Combination, **25:155-158**

Radiotherapy, **25:308-318**

Splenectomy, **23:61**

See also *lymphoma* and *chemotherapy*.

Hodgkin, Thomas

Biography of, **23:52-53**

Hormones

And cancer, **22:41-45,53**

Of the breast, **21:236-241**; **22:55,57-58**

For advanced prostate cancer, **23:284**

Huggins, Charles

Biography of, **22:230-231**

Humanism and cancer, **22:386-387**

Hutchinson's melanotic freckle

Differential diagnosis of malignant melanoma and, **23:168**

Hypercalcemia and cancer, **25:27-30**

Case history of, **25:27**

Causes of, **25:28-29**

Clinical presentation of, **25:28**

Pseudohyperparathyroidism, **25:29**

Hyperkeratosis of the larynx

Treatment of, **24:306**

Hyperpigmentation as a sign of internal cancer, **22:366,369**

Immunology, 21:134-140; 25:178-186, 187-197

Immune defects,

Associated with cancer, 25:179-182, 192

Associated with transplantation, 22:148-150

In Hodgkin's disease and other lymphomas, 21:351-355

Primary, 25:178-179

Treatment of, 25:185

Immune response, 25:188-189, 192, 194-195

Antigens and, 25:182-184, 187

In human tumors, 25:189-191

Tumor-associated, 25:187

Tumor-specific, 21:135-137; 25:187

Cellular, 25:188

Host resistance in, 24:106

Immunologic surveillance and, 25:178, 191-192

Initiation of, against cancer cells, 22:308-310

Production of antibody, 25:188-189

Suppression by blocking factors, 25:192

Immunotherapy, 21:137-138; 23:349-351; 25:184-186, 193-197

BCG, 25:162, 198-203

Clinical trials with, 25:202

Current status of, 25:162

Hazards of, 25:202-203

History of, 25:198

Mechanisms of action of, 25:201-202

Methods of administration, 25:198-201

For Burkitt's tumor, 23:350-351

For leukemia, 23:349-350, 351

For localized malignant melanoma, 23:350

Viruses and,

Mouse mammary tumor, 22:330-333

Infections in cancer patients, 23:138-150

Afflicted with Hodgkin's and other lymphomas, 21:351-354

Predisposing factors for, 23:138-140

Prevention of, 21:214-219; 23:145-147

Therapy for, 23:147-150

Types of, 23:140-145

Information services, 21:143-155, 305

Dial Access Libraries, 21:144-152

Editorial on, 21:200-201

MEDLARS, 21:146-152

Telephone, radio, and television conferences, 21:144-152

See also *Dial Access Programs*.

Interferon

And virus interference, 22:26-29

Induction with poly I:C, 22:28-29

In mouse mammary cancer, 22:333

International campaign against cancer, 24:368

Intradermal nevus

Differential diagnosis of malignant melanoma and, 23:163

Iodinated contrast studies for staging of lung cancer, 25:255-256

Isoenzymes, use in cancer management, 23:278

Isolation of cancer patients

Editorial on, 22:129

Issels Combination Therapy for cancer, 22:188-191

J

Jaw

Cancer of, 22:107-109

Burkitt's lymphoma,

First report of, 22:348-355

K

Kanfer Neuromuscular or Handwriting Test for cancer, 21:120-122

Kaposi's sarcoma, 22:180

Kidney

See *renal cell carcinoma*.

Krebiozen and Carcalon, 23:111-115

L

Laetrile, 22:245-251

Laminar air flow room as prophylaxis of infection in cancer patients, 21:214-219

Laparotomy, exploratory

In Hodgkin's disease and other lymphomas, 21:346-347

In children, 21:99-101

Larynx, hyperkeratosis of

Treatment of, 24:306

L-asparaginase

See *chemotherapy*.

Legislation on cancer

Editorial on, 21:332-333

National Cancer Act of 1971, 23:47-51

Purpose, 23:47-48

Strategy, 23:48-51

National cancer program, 25:343

Leiomyoma, 21:379

Leiomyosarcoma, 21:379-380

Of the colon, 25:102

Leukemia

Chemotherapy for, 23:347-349

Adriamycin, 24:327-328

Combination, 25:155-158

Immunotherapy trials and, 23:349-351

Clustering in, **25:230-234**
 First description of, **25:91-97**
 First remission in children, **24:294-305**
Lewis Methods for cancer, **22:312-317**
Life Island as prophylaxis of infection in cancer patients, **21:214-219**
Lipoproteins and cancer, **21:202-212**
Liposarcoma, treatment of
 In the thigh, **24:307**
Liver cancer
 Detection by,
 Alpha₁-Fetoprotein (AFP) levels, **25:210-211**
 Beta-S Feto protein (Beta-SFP) levels, **25:212**
 Metastatic,
 Treatment of, **23:180; 24:247**
Looking at Cancer, **21:63-65, 128-129, 190-192, 262-264, 322-324, 388-389; 22:66-67, 118-121, 198-199, 252-253, 322-323, 381-383; 23:68-69, 122-123, 189-192, 326-327, 383; 24:62-63, 128, 190-248-249, 308-311, 375-376; 25:40-41, 111, 166-169, 235, 301-302, 348**
Lung cancer, **24:87-95, 96-99; 25:242-256**
 Detection of, **25:210, 242-243**
 By CEA measurement, **25:210**
 Diagnosis of, **24:96-98**
 Histologic classification of, **25:243-250**
 Adenocarcinoma, **25:246-249**
 Bronchial adenoma, **25:249-250**
 Epidermoid carcinoma, **25:244-245**
 Large cell undifferentiated carcinoma, **25:249**
 Pancoast tumor, **25:250**
 Small cell undifferentiated carcinoma, (oat cell), **25:245-246**
 Metastases of, **25:256**
 Staging of, **25:250-256**
 Bronchography for, **25:254**
 Chest fluoroscopy for, **25:253, 255**
 Fluoroscopically assisted studies for, **25:254**
 General rules of, **24:87-89**
 Iodinated contrast studies for, **25:255-256**
 Linear tomography for, **25:253-254, 255**
 Mediastinoscopy for, **25:256**
 Specific considerations of, **24:89-92**
 Standard chest radiography for, **25:251-252, 255**
 TNM System for, **24:87-95; 25:252**
 Work sheet for, **24:95**
 Survival rates from, **24:147**
 Treatment of,
 Chemotherapy, **24:99, 327**
 Immunotherapy, **24:99**
 Radiotherapy, **24:98-99**
 Surgical resection, **24:98**

First description of, **24:238-242**
Lymph node dissection
 For malignant melanoma, **22:216-220**
 For testicular tumors, **25:279-280**
Lymphoepithelial lesions of the salivary glands, **24:270**
Lymphoma, malignant, **24:137-140**
 Classification of, **21:343-345, 374-377**
 Complications of, **21:351-355**
 Diagnosis of, **21:342-345, 374-377; 24:137-138**
 Incidence of, **21:342-343**
 Management, **21:355-358; 24:139-140**
 Chemotherapy, **21:356-358; 24:139**
 Adriamycin for, **24:327**
 Bleomycin for, **24:322**
 Immunotherapy, **24:140**
 Radiotherapy, **21:355-356; 24:139**
 Non-Hodgkin's lymphoma
 Advances in, **25:320**
 Staging, **25:321-327**
 Treatment, **25:327-333**
 For Stages III, III_S, and III_E, **25:327, 333**
 For Stage IV, **25:333**
 Oral cavity, **22:39, 212-213**
 Staging of, **21:344-351; 24:138-139**
 Gallium-67 scanning, **21:350-351**
 Laparotomy, **21:346-347, 350**
 Liver biopsy, **21:349-350**
 Splenectomy, **21:348, 350**
 See also *Burkitt's lymphoma and Hodgkin's disease.*
Lymph vessel tumors, **22:181-183**
 Lymphangioma, **22:181-183**
 Lymphangiosarcoma, **22:182-183**

M

Malignant effusions and metastatic carcinoma, **21:47-49**
 Cytologic examination of, **21:252-254**
Mammography for breast cancer detection, **21:158-161; 22:62; 24:83-84**
Martland, Harrison Stanford
 Biography of, **23:367**
Mastectomy
 First description of, **23:96-98**
 Subcutaneous bilateral,
 For chronic cystic mastitis, **24:246-247**
Mediastinoscopy
 For testicular tumors, **25:279-280**
 In lung cancer, **25:256**
Medical education in oncology
 Editorial on, **25:175-176**
Medical Information Services
 Evaluation of, **21:149-151**
 Organization of, **21:147-149**
 Specific techniques for, **21:143-147**
Meigs, Joe Vincent

Biography of, **25:31-32**
Melanoma, malignant, **24:225-228,338**
 Biopsy of, **24:104-105,233-235**
 Differential diagnosis of, **23:160-170**
 Benign pigmented nevi, **23:161**
 Blue nevus, **23:164**
 Compound nevus, **23:162**
 Hutchinson's melanotic freckle, **23:168**
 Intradermal nevus, **23:163**
 Malignant melanoma, **23:169-170**
 Pigmented basal cell carcinoma, **23:167**
 Sclerosing hemangioma, **23:166**
 Seborrheic keratosis, **23:165**
 Lymph node dissection for, **22:216-220: 23:42-45**
 Incontinuity versus discontinuous, **22:219-220**
 Oral cavity, **22:39,212-213**
 Pregnancy and, **25:164**
 Uveal,
 Enucleation for, **23:284**
 Metastasis of, **23:284**
Meningeal sarcoma
 Radiation therapy for, **25:163**
Meningiomas, **25:114-115**
Mesenchymal tumors (gonadal stromal) of the ovary, **24:345**
Metabolic abnormalities
 In anorexia and cachexia, **21:73-75**
Metastatic cancer
 From neuroblastoma, **23:116**
 Management of, **21:47-57**
 By anticoagulation, **23:38-41**
 Of the bone, **24:197,211**
 Of the breast,
 Therapy for, **21:236-247,306-316**
 Of the cervical lymph nodes,
 With unknown primary, **21:112-119**
 Of the colon, variables in, **21:32-35**
 Of the uveal, **23:284**
Methotrexate
 See *chemotherapy*.
Microscopic examination of tumors, **21:273-277**
Mixed tumors of the salivary glands, **24:268-272**
Mortality, cancer
 In Black population, **24:42-46**
 See also *statistics*.
M-P virus, **21:186-189**
Mucoepidermoid carcinoma, **24:270-271**
Müller, Johannes
 Biography of, **23:305-306**
Muscle tumors, **21:379-383**
 Leiomyoma, **21:379**
 Leiomyosarcoma, **21:379-380**
 Rhabdomyoma, **21:380-381**
 Rhabdomyosarcoma, **21:381**

Embryonal, **21:381-382**
 Pleomorphic, **21:382-383**
Myeloma, **24:204-205**

N

National Cancer Institute
 Chemotherapy program for evaluation of drugs, **22:99-101**
National Cancer Program, **23:106-110**
 Plan for, **23:47-51**
 Demonstration projects for, **23:107-109**
 Funding for, **23:109**
 Objectives of, **23:47-48,106-107**
 Planning sessions of, **23:50-51**
 Structure of, **23:49,109-110**
 Role of private sector in, **23:62-63,109**
National Wilms' Tumor Study, **24:75-76**
Needle aspiration
 See *breast*.
Nervous system metastases
 Management and effects of, **21:49-53**
 From a breast primary, **21:311-313**
Neuroblastoma, disseminated, **25:264-277**
 Case history of, **25:275**
 Diagnosis of, **25:265-268**
 Bone scans for, **23:116**
 Management of, **25:265**
 By chemotherapy, **25:268-269,272-277**
 By radiotherapy, **25:268-269,271-272**
 By surgery, **25:269-271**
Neurodiagnostic tests, **25:116**
Neurofibromatosis, multiple
 See *Von Recklinghausen's disease*.
Neuromuscular Handwriting Test for cancer, **21:120-122**
Nevi, benign
 Differential diagnosis of malignant melanoma and, **23:161-164**
Nitrosamines and cancer, **24:351,353**
Non-Hodgkin's lymphoma
 See *lymphoma*.
Nursing, cancer
 American Cancer Society's work study program in, **24:191-192**
Nutrition and cancer, **21:398-406**
 In animals, **21:399-402**
 In man, **21:402-404**
 Of the colon, **21:403-404**; **23:151-154**
 Of the liver, **21:404**
 Of the oropharynx and esophagus, **21:402-403**
 Of the stomach, **21:403**

O

Obstructive syndromes and metastases, **21:53-54**

Oncofetal antigen in pancreatic cancer, 25:212

Oncologist and cancer management, 24:320

Oncology

Pediatric, 24:332-335

See also *classics in oncology*.

Oncornavirus

See *virus*.

Oral cavity

Benign tumors of, 22:102-106

Fibroma, 22:103

Granular cell myoblastoma, 22:104

Hemangioma, 22:104

Lingual thyroid, 22:106

Median, rhomboid glossitis, 22:106

Mixed, 22:104

Mucocoele, 22:102

Papilloma, 22:103

Pyogenic granuloma, 22:103

Reparative giant cell granuloma, 22:104-105

Torus, 22:105

Treatment of, 22:210

Cancer of,

Adenocarcinoma, 22:38-39, 212, 213, 356

Diagnosis of, 22:30-39, 159-175

Biopsy, 22:159-162

Differential, 23:31-32

Exfoliative cytology for, 22:163-171

False-positive findings in, 22:169

Indications for, 22:163-166

Physical examination, 22:32-35

Roentgen examination, 22:108

Staining techniques, 22:172-175

Symptomatology, 22:31-34

Etiology of, 23:28-30

Follow-up after radiation treatment, 25:163

Jaw tumors, 22:107-109

Lymphomas, 22:39, 212-213

Melanoma, 22:39, 212-213

Plasmacytoma, 22:39

Sites of, 22:34-35

Squamous cell, 22:35-38, 210-213

Therapy for, 22:209-215

Palliative, 22:212, 214-215

Surgery, 22:74-75, 209-215, 303-307, 356

Orchiectomy for advanced prostatic cancer, 25:101

Osteoblastoma, 24:201

Osteochondroma, 24:198-199

Osteogenic sarcoma, 24:197, 207, 208-210

Osteoid osteoma, 24:200-201

Osteoma, 24:198

Osteoradionecrosis

In luminous watch dial painters, 23:367-374

Prevention of, 23:61

Ovarian cancer, 21:365-367; 25:159-161

And CEA levels, 24:350

And pregnancy, 24:349

Diagnosis of, 21:365-366; 22:357-359; 24:340-341

In children, 25:334-335

Histologic typing of, 25:160-161

Metastasis of, 24:346

Staging of, 24:341-342

Surface epithelial tumors of borderline malignancy, 25:159-161

Symptoms of, 24:339-341

Teratomas of, 25:292

Treatment of, 21:366-367; 24:342-347, 348-350

Chemotherapeutic, 24:347

Alkylating agents, 25:153

Of childhood, 25:335-337

Of epithelial cancer by stage, 24:342-344

Of nonepithelial cancer,

Germ cell tumors, 24:344-345

Gonadoblastoma, 24:345-346

Mesenchymal (Gonadal Stromal), 24:345

Radiation, 24:106, 346-347, 348

Surgical, 24:348-349, 350

Oxyphilic adenoma (oncocyoma) of the salivary glands, 24:270

P

Paget's disease of the breast,

First description of, 21:303-304

Pain control techniques, 23:269-274

Analgesics, 23:270-271

In metastatic cancer, 21:56

Peripheral nerve block, 23:272

Subarachnoid alcohol block, 21:248-251; 23:272-274

Subarachnoid saline injection, 23:273

Palliation

For incurable cancer, 21:47-57

Of the breast, 21:236-247, 306-316

Techniques for nutritional,

Bypass surgery,

For alimentary cancer, 22:74-79

For oral cavity cancer, 22:212-215

Pancoast tumor, 25:250

Pancreatic cancer

Diagnosis of, 24:148

Epidemiology of, 22:274-275

First surgical removal of pancreas for, 24:361-367

Head of pancreas,

Diagnosis of, 22:276-277, 282

Treatment of, 22:277-279, 282

Malignant islet cell tumors of,

Treatment with Streptozotocin, 25:153

- Measurement of CEA in, **25:25-26**
 Oncofetal antigen levels in, **25:212**
 Prognosis of, **22:279-280,282**
 Tail and body of,
 Diagnosis of, **22:280-281,282**
 Treatment of, **22:281-282**
- Papanicolaou, George**
 Biography of, **23:171-173**
- Papanicolaou's diagnostic test**, **23:174-179**
- Papovavirus**
See virus.
- Paraplegia and bladder cancer**, **24:107**
- Pathology**
 First systematic and codified text of, **24:47-48,49-56**
 Müller's treatise on, **23:307-312**
 Of cancer, **22:41-54**
 Functioning tumors, **22:41-45,53**
 Gross appearance and microscopic diagnosis of, **22:49**
 Metastases of, **22:45-50,53**
 Direct invasion, **22:45-46,53**
 Through lymphatics, **22:46-49,53**
 Through veins and arteries, **22:49-53**
 Radiotherapist and pathologist, **22:50-54**
See also diagnosis.
- Patients, cancer,**
 Decisions about, **23:155-159**
 Patient's role in choosing therapy, **23:181**
 Editorials on, **22:129,386-387**
 Emotional reactions of, **22:70-72,284-291; 24:36-39**
 Isolation systems for, **21:214-219**
 Life-threatening infections in, **23:138-150**
 Rights of, **25:98-100**
 Survival rates for, **25:338-343**
- Pelvic examination**
See gynecologic examination.
- Penis**
 Squamous cell cancer of,
 Etiologic relationship of podophyllin with, **25:291**
- Periosteal reaction** as a sign of bone cancer, **24:194-195,196**
- Peripheral nerve block**, **23:272**
- Plasmacytoma** of the oral cavity, **22:39**
- Pneumonectomy**
 First report of, **24:236-242,337**
- Podophyllin's relationship with cancer**, **25:291**
- Polycyclic hydrocarbons**, **24:354**
- Poly I:C** as interferon inducer, **22:26,28-29**
- Polyps, colorectal**
 Management of, **23:91-93,313**
- Pott, Sir Percival**
 Biography of, **24:108-109**
- Pregnancy**
 And breast cancer, **23:180**
 And melanoma of the sacrum, **25:164**
 And precancerous lesions of the cervix, **24:141-143**
- Proctosigmoidoscopy**, **24:160-162**
 Detection of colon and rectal cancer, **25:286-290**
 Tutorendoscope for teaching technique of, **23:354-361**
- Prolactin**
See breast.
- Prostate cancer**, **24:282-288**
 Diagnosis of, **24:283-284**
 Hormonal palliation of, **23:284**
 Incidence of, **24:282**
 Metastatic,
 First use of orchiectomy and estrogens for, **22:232-240**
 Orchiectomy for, **25:101**
 Staging of, **24:282-283,284**
 Treatment of, **21:109-111; 24:284-288**
 Palliative, **24:285-287**
 Radiotherapy, **25:73**
- Pseudohyperparathyroidism**, **25:29**
-
- Q**
- Quiz: Is It Cancer?**, **24:289**
-
- R**
- Radioactive isotopes** as treatment for malignant effusions, **22:143-146**
- Radiography, standard chest**
 For lung cancer, **25:251-252,255**
- Radioisotopic scanning**, **24:85**
- Radiology, diagnostic**, **24:83-86**
 Arteriography, **24:86**
 EMI scanning, **24:85-86**
 For bone tumors, **24:194-211**
 Lymphangiography, **24:86**
 Mammography, **24:83-84**
 Radioisotopic scanning, **24:85-86**
 Thermography, **24:84**
 Tomography, **24:84**
 Ultrasound, **24:84**
 Venography, **24:84**
 Xeroradiography, **24:83-84**
- Radionuclides**
 In cancer diagnosis, **21:292-301,334-340**
 Production of,
 By cyclotron, **21:334-340**
 Properties of specific ions, **21:337-340**
- Radiotherapy**
 Combined with actinomycin D,
 For soft tissue sarcomas, **23:268**
 For Wilms' tumor, **23:345**
 Combined with chemotherapy,

For Stage III childhood Hodgkin's disease, **23**:232-241
 Results of, **23**:238-241
 Staging of, **23**:232-234
 For bladder cancer, **23**:85-90
 For brain cancer, **25**:116-117
 For breast cancer,
 First X-ray therapy for, **22**:152
 Incurable, **21**:241-247,306-316
 Combined with systemic therapy, **21**:236-247
 Necrosis from, **21**:315
 For colon cancer, recurrent, **23**:302
 For Ewing's diffuse endothelioma of bone, **22**:94-98
 For head and neck cancer, **23**:61
 For Hodgkin's disease and other lymphomas, **21**:355-356; **25**:308-318
 For meningeal sarcoma, **25**:163
 For metastases,
 Of breast cancer, **21**:244-247,306-315
 Abdominal, **21**:314
 Bony, **21**:306-311
 Central nervous system, **21**:311-313
 Intrathoracic, **21**:244-247
 Soft tissue, **21**:313-315
 For neuroblastoma, disseminated, **25**:268-269,271-272
 For oral cavity cancer, **22**:209-215,356; **25**:163
 Palliative, **22**:212-214
 For ovarian cancer, **24**:346-347,348
 Postoperative, **24**:106
 For prostate cancer, **25**:73
 For stomach cancer, **23**:302
 For testicular tumors, **25**:279-280
 For Wilms' tumor, **24**:71-72,75
 Thyroid cancer development after, **25**:164-165
Rectal cancer
 Examination for, **24**:100-103
 Positions of, **24**:280
 Surgery for,
 Abdominal-perineal vs. fulguration, **21**:267-268
 First report of, **21**:361-364
Regional medical programs and cancer information services, **21**:147-152
Regression, spontaneous, **24**:274-279
 Occurrence of, **24**:274-275
 Possible causes of, **24**:275-279
Renal cell carcinoma, **25**:121-132
 Metastases of, **25**:122
 Natural history of, **25**:121-122
 Spontaneous regression of, **25**:125-129
 Staging and grading of, **25**:129-132
 Symptoms and signs of, **25**:122-125
 Endocrine, **25**:124-125
 Localized, **25**:123
 Systemic, **25**:124

Reporting on Cancer Research, **21**:68-70,123-124,193-195,255-257,325-327,394-396; **22**:68-69,122-123,196-197,254-255,320-321,379-380; **23**:66-67,120-121,184-186,263-264,320-322,381-382; **24**:58-59,123-124,188-189,250-252,312-314,377-378; **25**:44-45,105-106,170-171,236-237,299-300,345

Research methodology, **25**:58-61

Analysis, **25**:60-61
 Experimental design, **25**:60
 Formulating the hypothesis, **25**:58
 Interpretation, **25**:61
 Pretesting, **25**:59
 References, **25**:59

Reticulum cell sarcoma, **24**:197,205-206

Rhabdomyoma, **21**:380-381

Rhabdomyosarcoma, **21**:381-383

Embryonal, **21**:382

Pleomorphic, **21**:382-383

Rights of the cancer patient, **25**:98-100

RNA to DNA genetic transfer of information, **21**:36-38

Roentgenography of operative specimens in breast cancer, **21**:2-10,11-12

With Faxitron 804, **21**:11

Röntgen, Wilhelm K.

Biography of, **22**:151-152

S

Sacroccocygeal teratomas in children, **22**:202-208

Diagnosis of, **22**:204-206

Incidence of, **22**:202-203,208

Clinical presentation of, **22**:204-205

Differential, **22**:205-206

Pathology of, **22**:203-205

X-ray, **22**:205

Management of,

Surgical, **22**:206-207,208

Survival rates of, **22**:207-208

Salivary gland tumors

Benign, **24**:268-270

Lymphoepithelial lesions, **24**:270

Mixed, **24**:268-269

Oxyphilic adenoma (oncocytoma), **24**:270

Papillary cystadenoma lymphomatosum (Warthin's tumor), **24**:269

Diagnosis of, **24**:266-268

Biopsy for, **24**:268

Incidence of, **24**:266

Malignant, **24**:270

Adenocarcinoma, **24**:271,272-273

Acinic cell carcinoma, **24**:272-273

Adenocystic carcinoma (cylindroma), **24**:272

Mixed, **24**:271-272

- Mucoepidermoid carcinoma, **24:270-271**
 Squamous carcinoma, **24:273**
- Sarcomas**
 Adriamycin as treatment for, **24:326-327**
 Bleomycin as treatment for, **24:322**
 Classification of, **21:372-374**
 Smooth muscle, **21:379-380**
 Leiomyosarcoma, **21:379-380**
 Striated skeletal muscle, **21:380-383**
 Rhabdomyosarcoma, **21:381**
 Synovial tissue, **21:383-385**
 Synovial sarcoma, **21:384-385**
- Meningeal
 Radiation therapy for, **25:163**
- Osteogenic
 Diagnosis of, **23:74-75**
 First report of, in luminous watch dial painters, **23:367-374**
 Vaccine trials for, **23:74-80**
 Lysed cell vaccine, **23:76**
 Whole cell vaccine, **23:76-77**
- Ovarian, in children
 Treatment of, **25:335-337**
- Soft tissue,
 Diagnosis of, **23:266-267**
 Management of, **23:266-268**
 Chemotherapy, **23:268**
 Radiotherapy, **23:268**
 Surgery, **23:267-268**
- Scanning**, radionuclidic
 In the diagnosis of cancer, **21:292-301**
 Agents for, **21:294-301,334-340**
- Schiller iodine test** for cervical neoplasia, **24:23-24**
- Scintiscan**
 For evaluation of thyroid nodules, **23:281-283**
- Sclerosing hemangioma**, **23:166**
- Scott, Wendell G.**
 Obituary of, **22:260-261**
- Scrotal cancer** in children, **24:163-168**
 Age incidence of, **24:165**
 Clinical presentation of, **24:164**
 Diagnosis of, **24:166-167,168**
 Disease course of, **24:165-166**
 First description of, **24:108-116**
 Histologic types of, **24:163**
 Treatment of, **24:166-168**
- Seborrheic keratosis**, **23:165**
- Seminoma**, **25:88**
 Treatment of testicular, **24:244; 25:88**
- Serum**
 Lipoproteins in, **21:202-212**
- Skin disorders**
 As a sign of internal cancer, **22:364-371**
 Benign cutaneous lesions, **22:367-371**
 Erythema,
 Diffuse and variable, **22:365-369**
 Localized, **22:365,366**
 Hyperpigmentation, **22:366,369**
- Cancer,
 Basal cell carcinoma, **24:220-223**
 Nodulo-ulcerative basal carcinoma, **24:221**
 Superficial basal cell carcinoma, **24:221-223**
 Common sites of, **24:219-220**
 Danger signals for, **24:227**
 Diagnosis of, **24:218-220**
 Incidence of, **24:218-219**
 Melanoma, **23:160, 169-170; 24:225-228, 338**
 And pregnancy, **25:164**
 Lymph node dissection for, **23:42-45**
 Squamous cell carcinoma, **24:224-225**
 Therapy for,
 See chemotherapy.
- Smoking, cigarette**
 And risk of lung cancer, **23:362-366**
 Editorial on, **25:303-304**
 Effect on dogs, **21:78-94**
- Squamous cell carcinoma**
 Of the oral cavity, **22:35-38,212-213**
 Of the penis and podophyllin, **25:291**
 Of the salivary glands, **24:273**
 Of the skin, **24:224-225**
 Treatment, **24:244**
- Staging of tumors**, **21:368-370,377**
 Of Hodgkin's disease, **21:344-351**
 In children, **21:95-101**
 Of lung cancer, **24:87-94**
 Of lymphoma, **21:345-351**
- Statistics**, cancer, **21:13-31; 22:2-20; 23:2-27; 24:2-21; 25:2-21,159**
 For Black population, **24:42-46**
 For prostate cancer, **24:282**
- Stilbestrol**
 And contraceptive pills, **24:31**
 And vaginal cancer, **22:292-295**
- Stomach cancer**, **23:286-304**
 Diagnosis of, **23:288-293**
 Etiology of, **23:286-288**
 First gastrectomy for palliation of, **22:296-302**
 Incidence of, **23:286-287**
 Recurrence of, **23:300-301**
 Scirrhus, **24:47-50**
 Surgery for, **23:293-300**
 Bypass, **22:76-77,311**
 Palliative, **23:300**
 Survival of patients with, **23:302,303**
- Streptozotocin** in the treatment of malignant islet cell tumors of the pancreas, **25:153**
- Subarachnoid alcohol block** for pain control, **21:249-251**

Surgery

Bypass

For nutritional palliation in alimentary tract cancer, **22:74-79,311**

Elective neck dissection

Criteria for, **22:110-112**

For bladder cancer, **23:84-90**

For brain cancer, **25:116**

Disseminated neuroblastoma, **25:269-271**

For breast cancer, **22:55-56,58,62**

During pregnancy, **23:180**

Radical mastectomy for,

ACS policy statement on, **23:341-343**

Controversy over radical vs. conservative surgery, **23:330-333,334-338,339-340; 24:78-82**

First description of, **23:94-98**

For cecum cancer with liver metastasis, **23:180**

For effusions, recurrent malignant, **22:146**

For Hodgkin's disease,

Splenectomy, **23:61**

For melanoma, **22:212-213**

Lymph node dissection, **22:216-220; 23:42-45**

Incontinuity versus discontinuous, **22:219-220**

For oral cancer,

Palliative, **22:212-215**

Reconstruction and rehabilitation, **22:303-307**

Versus radiotherapy, **22:209-215,356**

For pancreatic cancer,

Body and tail, **22:281-282**

Head, **22:277-279,282**

For sacrococcygeal teratomas in children, **22:202-208**

For soft tissue sarcoma, **23:267-268**

For stomach cancer, **23:293-300**

For testicular tumors,

Versus radiation therapy and retroperitoneal node dissection, **25:279-280**

For Wilms' tumor, **24:71**

Gastrectomy,

First report of, **22:296-302**

Orchiectomy combined with estrogens, For metastatic cancer,

First report of, **22:230-240**

Survival rates of cancer patients, **25:338-343**

Editorial on, **25:239-240**

Synovium

Tumors of, **21:383-385**

Ganglion, **21:383**

Giant cell tumor of tendon sheath,

21:383-384

Synovial sarcoma, **21:384-385**

T

Teratocarcinoma

Treatment of testicular, **25:88**

Teratoma of the ovary, **25:292**

See also sacrococcygeal teratomas.

Testicular tumors

Detection by alpha₁-fetoprotein (AFP), **25:211**

Diagnosis of, **25:85-86**

Etiology of, **25:82**

Staging of, **25:82-85**

Treatment of, **25:86-89**

Chemotherapy, **23:345; 25:89**

Choriocarcinoma, **25:88-89**

Disseminated disease, **25:89**

Embryonal carcinoma, **25:88**

Regional node disease, **25:87-88**

Seminoma, **25:88**

Surgery vs. radiotherapy, and retroperitoneal lymph node dissection, **25:279-280**

Teratocarcinoma, **25:88**

Testis cancer

Bleomycin as treatment of, **24:324**

Treatment for seminoma of the, **24:244,337-338**

See also scrotum.

Thermography, **24:84**

Thyroid cancer

Differential diagnosis of, **23:281-283**

See also adenocarcinoma.

TNM System

For esophageal cancer, **25:50-55**

For lung cancer, **25:252**

Tomography

, **24:84**

For lung cancer, **25:253-254,255**

Trabeculation of bone cancer, **24:194,196**

Transition zone of bone cancer, **24:194,196**

Transplantation

And cancer incidence, **22:148-150**

As cancer therapy, **22:150**

Tumor-specific immunology in humans, **21:135-137**

Tutoredendoscope

For proctosigmoidoscopy, **23:354-361**

U

Ultrasound, **24:84**

Undifferentiated lung carcinoma

Large cell, **25:249**

Small cell, **25:245-246**

Unproven methods of cancer management, **25:66-71**

Bonifacio anticancer goat serum, **21:43-45**

Contreras methods, **21:317-321**

Editorial on, **21:71**

Ferguson plant products, **22**:113-117
Gerson method, **23**:314-317
Grape diet, **24**:144-146
Haematoxylin dissolved in Dimethylsulphoxide (D.M.S.O.), **21**:386-387
Issels combination therapy, **22**:188-191
Kanter neuromuscular or handwriting test, **21**:120-122
Krebiozen and Carcalon, **23**:111-115
Laetrile, **22**:245-251
Lewis methods, **22**:312-317
M-P virus, **21**:186-189

Uterine cervix

Bleomycin as agent for, **24**:322
Precancerous lesions in pregnancy, **24**:141-143

V

Vaccines, cancer virus, **24**:212-217
Feline leukemia-sarcoma complex, **24**:216-217
For herpesvirus, **24**:214-215,216
For osteogenic sarcoma, **23**:74-80

Vaginal cancer

Association with stilbestrol, **22**:292-295

Viewing the Journal of the National Cancer Institute, **21**:58-62,125-127,196-197,258-261,328-331,390-391; **22**:64-65,127-128,194-195,257-259,324-326,384-385; **23**:70-71,124-126,187-188,260-262,318-319,378-380; **24**:60-61,119-122,185-187,253-254,318-319,372-374; **25**:46-47,107-110,172-174,238,293-294,344

Vinyl chloride and cancer, **24**:352,353

Virchow, Rudolf

Biography of, **25**:91-92

Viruses and cancer, **21**:36-38; **23**:127-136; **25**:215-219,230

Adenoviruses, **23**:132; **25**:216

Herpesviruses, **23**:132-135; **24**:214-215, 258-264; **25**:222-223

Characteristics of, **25**:222-223

Epstein-Barr virus, **25**:222,225-226
And Burkitt's lymphoma, **25**:225-226

And nasopharyngeal carcinoma, **25**:226

Herpes Genitalis

Primary, **24**:258-259

Recurrent, **24**:259

Relation with cervical cancer, **24**:261-264; **25**:226-228

Treatment of, **24**:260-261

In animal tumors, **25**:223-225

In Burkitt's lymphoma, **22**:346

Of the breast, **22**:58-59,61

In animals, **22**:329-335

Mouse mammary tumor virus, **22**:330-333

In humans, **22**:329,330,334-335

Oncornaviruses, **23**:193-200; **25**:216-222,228-229

Characteristics of, **23**:193-195; **25**:216

B-type, **25**:216-222

C-type, **25**:216-219

Rous sarcoma virus

First report of transmissions of, **22**:21-25

Viogene-oncogene theory of, **24**:213-214

Von Recklinghausen's disease, **21**:174-183

Associated factors of, **21**:174-175

Incidence of, **21**:174

Natural history of, **21**:176-180

Prognosis of, **21**:180-183

W

Warthin's tumor, **24**:269

Wertheim operation

First report of, **25**:31-39

Wilms' tumor

Bilateral, **24**:75

Clinical manifestations of, **24**:66-67

Diagnosis of, **24**:67-69

Incidence of, **24**:66

National study of, **24**:75-76

Pathology of, **24**:70

Staging of, **24**:69-70

Survival from, **24**:75-76

Treatment of, **24**:70-76

Chemotherapy, **23**:345; **24**:73-75,233

Radiotherapy, **23**:345; **24**:71-72,75-76

Surgery, **23**:345; **24**:71

X

Xeroradiography, **24**:83-84

X-rays

Discovery of, **22**:151-152,153-157

Z

Zen Macrobiotic diet for cancer, **22**:372-375

